Latest news with #SeresTherapeutics
Yahoo
2 days ago
- Business
- Yahoo
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities
The human microbiome market is projected to expand at a CAGR of 20.42%, growing from $941.215 million in 2025 to $2.38 billion by 2030. This growth is driven by rising lifestyle diseases, an aging populace, and biomedical tech advances. Challenges include low awareness and government restrictions. The comprehensive report explores market trends, technological advancements, and regulatory impacts, featuring key players like Seres Therapeutics and Ferring Pharmaceuticals. It's essential for businesses targeting market entry, opportunity assessment, and strategic decision-making. Human Microbiome Market Dublin, June 19, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome Market - Forecasts from 2025 to 2030" has been added to offering. The global human microbiome market is projected to expand at a robust CAGR of 20.42%, reaching approximately US$2.38 billion by 2030, up from US$941.215 million in 2025. This growth is primarily driven by escalating cases of lifestyle diseases, an increase in diarrheal infections, significant lifestyle shifts across populations, and a growing elderly demographic. The market also benefits from advancing technology in biomedical sciences and increased investment in research. Despite these positives, challenges such as insufficient awareness about prebiotics and probiotics and regulatory constraints pose significant obstacles for key market players. Market Trends: Comprehensive Market Analysis: The global human microbiome market report offers an exhaustive examination of the sector, providing valuable insights and data-backed forecasts essential for strategic planning and understanding the market trajectory. Strategic Insights for Decision-makers: Updated regularly, the report provides crucial intelligence on market trends, emergent opportunities, and competitive dynamics. It delves into consumer demand across therapeutics, diagnostics, and probiotics, analyzing purchasing behaviors and key segments like healthcare providers, pharmaceutical companies, and consumers. Technological and Regulatory Exploration: The report investigates advancements such as next-generation sequencing and microbiome-based drug innovations, while also reviewing the regulatory landscape including policies on personalized medicine. This helps stakeholders strategize effectively in a rapidly advancing market. Key Benefits of this Report: Insightful Analysis: Comprehensive insights covering major and emergent geographical markets, focusing on consumer segments, governmental policies, and industry verticals. Competitive Landscape: Analysis of strategies employed by key players to guide market entry and growth tactics. Market Drivers & Future Trends: An exploration of market dynamics and trends shaping the industry's future. Actionable Recommendations: Leverage insights for strategic decisions, uncovering new business opportunities in a dynamic environment. Diverse Audience: Useful for startups, research institutions, consultants, SMEs, and large enterprises. Report Coverage: Data from 2022 to 2024 with forecasts from 2025 to 2030 Growth opportunities, challenges, supply chain outlook, regulatory framework, and trends Competitive positioning, strategies, and market share analysis Revenue growth forecast for segments and regions, including countries Company Profiling: Strategies, Product Offerings, Financial Data, and Developments Seres Therapeutics Microbiome Therapeutics Innovation Group Vedanta Biosciences Inc. Metabiomics Ferring Pharmaceuticals Finch Therapeutics BiomeBank Biohm Technologies Resbiotic Immuron Limited Maat Pharma Market Segmentation: Product Categories: Probiotic, Prebiotics, Supplements, Others Disease Categories: Diabetes, Autoimmune Disorder, Cancer, Obesity, Others Application Categories: Diagnostics, Therapeutics Regional Coverage: North America, South America, Europe, Middle East and Africa, Asia Pacific Key Attributes: Report Attribute Details No. of Pages 148 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $941.22 Million Forecasted Market Value (USD) by 2030 $2380 Million Compound Annual Growth Rate 20.4% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Microbiome Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Medscape
2 days ago
- Health
- Medscape
Shaping the Microbiome to Improve Cancer Immunotherapy
WASHINGTON — For years, oncologist Jonathan Peled, MD, PhD, and his colleagues at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City have been documenting gut microbiota disruption during allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its role in frequent and potentially fatal bloodstream infections (BSIs) in the first 100 days after transplant. Modulating microbiome composition to improve outcomes after allo-HSCT for hematological malignancies is a prime goal, and at the Gut Microbiota for Health (GMFH) World Summit 2025, Peled shared two new findings. In one study, his team found that sucrose can exacerbate antibiotic-induced microbiome injury in patients undergoing allo-HSCT — a finding that 'raises the question of whether our dietary recommendations [for] allo-HSCT patients are correct,' said Peled, assistant attending at MSKCC, during a session on the gut microbiome and oncology. And in another study, they found that a rationally designed probiotic formulation may help lower the incidence of bacterial BSIs. In December 2024, the probiotic formulation (SER-155, Seres Therapeutics, Inc.) was granted breakthrough therapy designation by the FDA. With immunotherapies more broadly, researchers are increasingly looking at diet and modulation of the microbiome to improve both treatment tolerance and efficacy, experts said at the meeting convened by the American Gastroenterological Association and the European Society of Neurogastroenterology and Motility. 'Cancer patients and caregivers are asking, 'What should I eat?'' said Carrie Daniel-MacDougall, PhD, MPH, a nutritional epidemiologist at the University of Texas MD Anderson Cancer Center in Houston. 'They're not just focused on side effects — they want a good outcome for their treatment, and they're exploring a lot of dietary strategies [for which there] is not a lot of evidence.' Clinicians are challenged by the fact that 'we don't typically collect dietary data in clinical trials of cancer drugs,' leaving them to extrapolate from evidence-based diet guidelines for cancer prevention, Daniel-MacDougall said. But 'I think that's starting to shift,' she said, with the microbiome being increasingly recognized for its potential influences on therapeutic response and clinical trials underway looking at 'a healthy dietary pattern not just for prevention but survival.' Diet and Probiotics After allo-HSCT The patterns of microbiota disruption during allo-HSCT — a procedure that includes antibiotic administration, chemotherapy, and sometimes irradiation — are characterized by loss of diversity and the expansion of potentially pathogenic organisms, most commonly Enterococcus , said Peled. This has been demonstrated across transplantation centers. In a multicenter, international study published in 2020, the patterns of microbiota disruption and their impact on mortality were similar across MSK and other transplantation centers, with higher diversity of intestinal microbiota associated with lower mortality. Other studies have shown that Enterococcus domination alone (defined arbitrarily as > 30% of fecal microbial composition) is associated with graft vs host disease and higher mortality after allo-HSCT and that intestinal domination by Proteobacteria coincides temporally with BSIs, he said. Autologous fecal microbiota transplantation (FMT) has been shown to largely restore the microbiota composition the patient had before antibiotic treatment and allo-HSCT, he said, making fecal sample banking and posttreatment FMT a potential approach for reconstituting the gut microbiome and improving outcomes. But 'lately we've been very interested in diet for modulating [harmful] patterns' in the microbiome composition, Peled said. In the new study suggesting a role for sugar avoidance, published last year as a bioRxiv preprint, Peled and his colleagues collected real-time dietary intake data (40,702 food entries) from 173 patients hospitalized for several weeks for allo-HSCT at MSK and analyzed it alongside longitudinally collected fecal samples. They used a Bayesian mixed-effects model to identify dietary components that may correlate with microbial disruption. 'What jumped out as very predictive of a low diversity fecal sample [and expansion of Enterococcus ] in the 2 days prior to collection was the interaction between antibiotics and the consumption of sweets' — foods rich in simple sugars, Peled said. The relationship between sugar and the microbiome occurred only during periods of antibiotic exposure. 'And it was particularly perplexing because the foods that fall into the 'sweets' category are foods we encourage people to eat clinically when they're not feeling well and food intake drops dramatically,' he said. This includes foods like nutritional drinks or shakes, Italian ice, gelatin dessert, and sports drinks. (In a mouse model of post-antibiotic Enterococcus expansion, Peled and his co-investigators then validated the findings and ruled out the impact of any reductions in fiber.) In addition to possibly revising dietary recommendations for patients undergoing allo-HSCT, the findings raise the question of whether avoiding sugar intake while on antibiotics, in general, is a way to mitigate antibiotic-induced dysbiosis, he said. To test the role of probiotics, Peled and colleagues collaborated with Seres Therapeutics on a phase 1b trial of an oral combination (SER-155) of 16 fermented strains 'selected rationally,' he said, for their ability to decolonize gut pathogens, improve gut barrier function (in vitro), and reduce gut inflammation and local immune activation. After a safety lead-in, patients were randomized to receive SER-155 (20) or placebo (14) three times — prior to transplant, upon neutrophil engraftment (with vancomycin 'conditioning'), and after transplant. 'The strains succeeded in grafting in the [gastrointestinal] GI tract…and some of them persisted all the way through to day 100,' Peled said. The incidence of pathogen domination was substantially lower in the probiotic recipients compared to an MSK historical control cohort, and the incidence of BSIs was significantly lower compared to the placebo arm (10% vs 43%, respectively, representing a 77% relative risk reduction), he said. Diet and Immunotherapy Response: Trials at MD Anderson One of the first trials Daniel-MacDougall launched at MD Anderson on diet and the microbiome randomized 55 patients who were obese and had a history of colorectal cancer or precancerous polyps to add a cup of beans to their usual diet or to continue their usual diet without beans. There was a crossover at 8 weeks in the 16-week BE GONE trial; stool and fasting blood were collected every 4 weeks. 'Beans are a prebiotic super-house in my opinion, and they're also something this population would avoid,' said Daniel-MacDougall, associate professor in the department of epidemiology at MD Anderson and faculty director of the Bionutrition Research Core and Research Kitchen. 'We saw a modest increase in alpha diversity [in the intervention group] and similar trends with microbiota-derived metabolites' that regressed when patients returned to their usual diet, she said. The researchers also documented decreases in proteomic biomarkers of intestinal and systemic immune and inflammatory response. The impact of diet on cancer survival was shown in subsequent research, including an observational study published in Science in 2021 of patients with melanoma receiving immune checkpoint blockade (ICB) treatment. 'Patients who consumed insufficient dietary fiber at the start of therapy tended to do worse [than those reporting sufficient fiber intake],' with significantly lower progression-free survival, Daniel-MacDougall said. 'And interestingly, when we looked at dietary fiber [with and without] probiotic use, patients who had sufficient fiber but did not take probiotics did the best,' she said. [The probiotics were not endorsed or selected by their physicians.] Now, the researchers at MD Anderson are moving into 'precision nutrition' research, Daniel-MacDougall said, with a phase 2 randomized, double-blind trial of high dietary fiber intake (a target of 50 g/d from whole foods) vs a healthy control diet (20 g/d of fiber) in patients with melanoma receiving ICB. The study, which is underway, is a fully controlled feeding study, with all meals and snacks provided by MD Anderson and macronutrients controlled. Researchers are collecting blood, stool, and tumor tissue (if available) to answer questions about the microbiome, changes in systemic and tissue immunity, disease response and immunotherapy toxicity, and other issues.
Globe and Mail
07-05-2025
- Business
- Globe and Mail
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the 'Investors and News' section of the Seres website at A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. About Seres Therapeutics Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit
